G

Gossamer Bio

Clinical-stage biopharma developing seralutinib for PAH

Overview

Gossamer Bio develops seralutinib for pulmonary arterial hypertension (PAH) and PH-ILD. The drug is an inhaled dry-powder small-molecule that inhibits multiple kinases (PDGFRα/β, CSF1R, c-KIT) in the lungs to maximize local effect and reduce systemic exposure. It differentiates itself with lung-focused inhalation delivery and a strategic partnership with Chiesi that provides funding and a pathway to commercialization, while it finances operations through equity and licensing rather than product sales. The company aims to complete the PROSERA Phase 3 trial in PAH (results due February 2026) and advance SERANATA for PH-ILD toward regulatory approval.

Work here?Claim your company

About Gossamer Bio

Simplify's Rating
Why Gossamer Bio is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

BiotechnologyHealthcare

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, CA

Founded

2017

Get referred to Gossamer Bio

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Gossamer submitted seralutinib NDA in September 2026, creating a 2027 approval path.
  • Third-quarter 2026 revenue reached $38.4 million, boosted by the Chiesi rights reacquisition.
  • A structured private placement can provide up to $250 million for launch preparation.

What critics are saying

  • PROSERA missed its primary endpoint in February 2026, weakening approval odds.
  • Gossamer warned its second $125 million financing closes only if FDA accepts NDA by December 31, 2026.
  • If FDA rejects seralutinib, Gossamer faces continued going-concern risk and possible operating shutdown.

What makes Gossamer Bio unique

  • Seralutinib targets PAH with inhaled delivery, focusing on lung-local kinase inhibition.
  • Gossamer reacquired worldwide seralutinib rights from Chiesi in 2026, controlling commercialization.
  • The FDA cited PROSERA significance as review issues, not filing issues, in June 2026.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.2B

Above

Industry Average

Funded Over

6 Rounds

Private Placement VC funding comparison data is currently unavailable. We're working to provide this information soon!
Private Placement VC Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Disability Insurance
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options

Stock Price

Company News

MarketScreener
Nov 10th, 2026
Gossamer Bio files seralutinib NDA, unlocking up to $125M more funding on FDA acceptance

Gossamer Bio submitted its first New Drug Application to the US Food and Drug Administration (FDA) in September 2026 for seralutinib, a treatment for pulmonary arterial hypertension. The company aims for a potential launch in 2027. FDA acceptance of the application in 2026 would unlock up to about $125 million in committed capital from a private placement, which has already provided $25 million upfront. Warrants tied to FDA approval could add up to about $100 million. Third-quarter revenue rose to $38.4 million from $13.3 million a year earlier, mainly from the end of its Chiesi collaboration and the reacquisition of worldwide rights to the drug. Net loss was $48.1 million, and cash stood at $51.2 million on September 30, 2026. Gossamer also completed a 1-for-80 reverse stock split to regain Nasdaq compliance.

Yahoo Finance
Sep 16th, 2026
Gossamer Bio appoints Baupost veteran Greg Ciongoli to board as seralutinib nears FDA path

Gossamer Bio (Nasdaq: GOSS) has appointed Greg Ciongoli to its board of directors, effective September 16, 2026. He will also sit on the audit committee. Ciongoli founded Boston-based investment firm Adiumentum Capital Management in April 2024. He was previously a partner at the Baupost Group, and he serves on the boards of REGENXBIO, Zymeworks, and Atara Biotherapeutics. The San Diego company is a clinical-stage biopharmaceutical business developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Chief executive officer Faheem Hasnain said Ciongoli's investment experience will help as the company advances seralutinib toward potential US Food and Drug Administration approval.

StreetInsider
Aug 21st, 2026
Gossamer Bio secures $250M private placement with $150M committed for seralutinib PAH approval

Gossamer Bio has secured a structured private placement financing of up to $250 million to fund development of seralutinib, a treatment for pulmonary arterial hypertension and related conditions. The deal includes $150 million in committed capital: $25 million at initial closing and $125 million upon FDA acceptance of the seralutinib new drug application in 2026. Investors will also receive warrants exercisable upon FDA approval, potentially providing an additional $100 million if exercised in full. The financing involves participation from new and existing institutional investors, including EcoR1 Capital, 683 Capital Partners, RA Capital Management, and others. Gossamer Bio plans to submit the NDA in September 2026. The company expects the proceeds, combined with existing cash resources, will fund operations into 2028. Leerink Partners and Cantor are serving as joint placement agents.

Business Wire
Aug 13th, 2026
Gossamer Bio reacquires worldwide rights to seralutinib, cuts debt by $115.9M ahead of September NDA submission

Gossamer Bio reported second quarter 2026 financial results and announced it plans to submit a New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026. The company held a Pre-NDA Type B meeting with the FDA in mid-June and received official minutes characterising statistical significance concerns as review issues rather than filing issues. The company reacquired worldwide rights to seralutinib from Chiesi, which paid Gossamer $5 million to settle all obligations. Gossamer exchanged approximately $181.1 million of convertible notes, reducing debt by roughly $115.9 million. Cash and marketable securities totalled $57.0 million as of 30 June 2026, expected to fund operations into the first quarter of 2027. Research and development expenses decreased to $26.4 million from $41.6 million year-over-year. The company reported net income of $16.9 million for the quarter.

Yahoo Finance
Jun 17th, 2026
Gossamer Bio slashes debt from $200M to $72M, extends maturity to 2030

Gossamer Bio has reduced its convertible debt from $200 million to under $72 million through a note exchange, extending maturity to 2030 with 7.5% semiannual cash interest. The company reported $99 million in cash and cash equivalents as of 31 March 2026, with runway extending into Q1 2027. The company's Phase III Procera study of seralutinib showed a placebo-adjusted improvement of 13.3 metres in six-minute walk distance, though it didn't meet the prespecified statistical significance threshold. Gossamer has advanced FDA discussions from a Type C to a Type B pre-NDA meeting. The company implemented a significant reduction in force affecting approximately half its workforce and expects lower operating expenses following the wind-down of the Procera study.

Recently Posted Jobs

Sign up to get curated job recommendations

Gossamer Bio is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs